Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Distribution of women with different quality of life scores in each arm of the EPHT Trial over time

From: Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial

  EQ-5D score
Survey year/trial arm Minimum 1st quartile Median 3rd quartile Maximum
2nd year      
   Non-blind HT 0.30 0.80 0.90 1.00 1.00
   Non-treatment 0.40 0.70 0.90 1.00 1.00
   Blind HT 0.30 0.80 0.90 1.00 1.00
   Blind placebo 0.30 0.80 0.90 1.00 1.00
Final      
   Non-blind HT 0.40 0.70 0.80 0.90 1.00
   Non-treatment 0.30 0.70 0.80 0.90 1.00
   Blind HT 0.30 0.70 0.80 0.90 1.00
   Blind placebo 0.10 0.70 0.80 0.90 1.00
  1. EQ-5D – quality of life according to EQ-5D score
  2. HT – hormone therapy